Carbamazepine increases atherogenic lipoproteins: mechanism of action in male adults
- 1 February 2002
- journal article
- clinical trial
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 282 (2) , H704-H716
- https://doi.org/10.1152/ajpheart.00580.2001
Abstract
Treatment with carbamazepine (CBZ) affects cholesterol concentrations, but little is known about the precise nature and underlying mechanisms of changes in lipoprotein metabolism. We investigated prospectively the effects of CBZ on lipid metabolism in normolipemic adults. In 21 healthy males, lipoprotein and noncholesterol sterol concentrations were measured before and during treatment with CBZ for 70 ± 18 days. Thirteen subjects underwent kinetic studies of apolipoprotein-B (ApoB) metabolism with the use of endogenous stable isotope labeling. Lipoprotein kinetic parameters were calculated by multicompartmental modeling. Significant increases in total cholesterol, in ApoB-containing lipoproteins [very-low-density lipoprotein (VLDL), intermediate density lipoprotein (IDL), and low-density lipoprotein (LDL)], and in triglycerides, but not in high-density lipoprotein (HDL), were observed. Lipoprotein particle composition remained unchanged. Mean fractional catabolic and production rates of ApoB-containing lipoproteins were not significantly different, although mean production rates of VLDL and IDL were substantially increased (+46 ± 139% and +30 ± 97%, respectively), whereas mean production of LDL remained unchanged (+2.1 ± 45.6%). Cholestanol in serum increased significantly but not the concentrations of plant sterols (campesterol, sitosterol) and the cholesterol precursors (lathosterol, mevalonic acid). There was a significant correlation between the decrease in free thyroxine and the increase in IDL cholesterol. Treatment with CBZ increases mainly ApoB-containing lipoproteins. CBZ seems not to influence endogenous cholesterol synthesis or intestinal absorption directly. The increase is neither related to increased ApoB production nor to decreased catabolism but is rather due to changes in the conversion cascade of IDL particles, most likely as an indirect effect through a decrease in thyroid hormones.Keywords
This publication has 39 references indexed in Scilit:
- Thyroxine inversely regulates serum intermediate density lipoprotein levels in children with congenital hypothyroidismPediatrics International, 1999
- Increased High‐Density Lipoprotein Cholesterol in Patients with Epilepsy Treated with Carbamazepine: A Gender‐Related StudyEpilepsia, 1999
- Hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 studied with a stable isotope technique in men with visceral obesityInternational Journal of Obesity, 1998
- Effect of thyroid hormone on plasma apolipoproteins and ApoA‐ and ApoB‐containing lipoprotein particlesEuropean Journal of Clinical Investigation, 1998
- Thyroid replacement therapy and its influence on postheparin plasma lipases and apolipoprotein-B metabolism in hypothyroidismJournal of Clinical Endocrinology & Metabolism, 1993
- HDL Metabolism and AtherosclerosisJournal of Cardiovascular Pharmacology, 1990
- Mortality from ischaemic heart disease among patients using anticonvulsive drugs: a case-control study.BMJ, 1985
- Serum lipids and anticonvulsantsActa Neurologica Scandinavica, 1982
- Plasma High-Density Lipoprotein Cholesterol in Epileptics Treated with Various AnticonvulsantsEuropean Neurology, 1980
- Plasma high-density lipoprotein cholesterol and hepatic cytochrome P-450 concentrations in epileptics undergoing anticonvulsant treatmentScandinavian Journal of Clinical and Laboratory Investigation, 1980